Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 116 record(s)

Req # A-2021-000306

Adverse Reaction Reports (AERs) for Zostavax II. Report numbers: E2B_01333350, E2B_01438894, E2B_01440660, E2B_01497636.

Organization: Health Canada

63 page(s)
September 2021

Req # A-2021-000310

Adverse Reaction Reports (AERs) for Pantoprazole sodium. Report numbers: E2B_03769405, E2B_03729839, E2B_03732541, E2B_03723458, E2B_03742382, E2B_03747427, E2B_03765922, E2B_03720802, E2B_03764326, 936581. AERs for Pantoprazole magnesium. Report numbers: E2B_03757188, E2B_03758098. AERs for Amphetamine. Report numbers: E2B_03728613, E2B_03709420, 934844, 935569. AERs for Mezavant. Report numbers: 936025, E2B_03718635.

Organization: Health Canada

518 page(s)
September 2021

Req # A-2021-000321

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-104168-654, Establishing the Office of the Chief Data Officer.

Organization: Health Canada

15 page(s)
September 2021

Req # A-2021-000333

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-104611-600, Response to subsection 37(1) Letter from the Information Commissioner.

Organization: Health Canada

9 page(s)
September 2021

Req # A-2021-000358

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-101485-157.

Organization: Health Canada

48 page(s)
September 2021

Req # A-2021-000377

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-102837-585.

Organization: Health Canada

24 page(s)
September 2021

Req # A-2021-000381

Adverse Reaction Reports (AERs) for Cancidas. Report numbers: E2B_02569986, E2B_02595082, E2B_02610152, 000723631, 000723632, E2B_02466827, 000725992, E2B_02484977, 000725996, E2B_02546063.

Organization: Health Canada

103 page(s)
September 2021

Req # A-2021-000382

All registration, renewal, amendment or discontinuance applications and Pest Management Regulatory Agency (PMRA) responses for registered Chlorpyrifos products from the years 2006 to 2021.

Organization: Health Canada

26 page(s)
September 2021

Req # A-2021-000390

Documentation which indicates the standard adopted by this institution for a positive covid-19 test: Unvaccinated people. Partially vaccinated people-one dose. Fully vaccinated people-two doses or one dose J&J. CLASS OF RECORDS, NUMBER AND TITLE.

Organization: Health Canada

0 page(s)
September 2021

Req # A-2021-000400

Adverse Reaction Reports (AERs). Report numbers: E2B_03063086, E2B_03075820, E2B_03056199, E2B_03199474, E2B_03199475, E2B_03275824, E2B_03401689, E2B_03317883, E2B_03432448, E2B_03441760, E2B_02278967, E2B_02525736, E2B_02780094, E2B_02934774, E2B_02872720, 000911715, 000924703, 000934109, 000924983, E2B_03064119.

Organization: Health Canada

457 page(s)
September 2021
Date modified: